SCHEMBL1106083

SCHEMBL1106083

CC(C)[C@H]1[C@@H](C(C)C)OC(=O)[C@@H]1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13589504 1.00 — —
SCHEMBL10035728 0.83 — —
SCHEMBL17973347 0.83 — —
SCHEMBL10110534 0.81 MEN1 (0.31) —
SCHEMBL12833579 0.73 HIF1A (0.34) —
SCHEMBL677557 0.72 — —
SCHEMBL13120130 0.72 HIF1A (0.35) —
SCHEMBL14503356 0.72 — —
SCHEMBL13105442 0.72 HIF1A (0.35) —
SCHEMBL1106112 0.71 HIF1A (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157403-A1 BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS CHACKALAMANNIL SAMUEL (US) 2012-06-21 — — US disclosed
US-8153664-B2 thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer SCHERING CORPORATION (US) 2012-04-10 — — US disclosed
US-20080090830-A1 Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists SCHERING CORPORATION 2008-04-17 — — US disclosed
Send feedback